XERIS BIOPHARMA HOLDINGS, INC. Tax Withholding Paid on Stock Awards
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Tax Withholding Paid on Stock Awards of $17.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $191.00K, a 77.79% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $17.02M, a 112.77% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.54M, a 827.71% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $478.00K, a 475.90% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $10.88M, a 191.27% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $3.73M, a 270.07% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $1.01M, a 115.60% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $468.00K, a 12.36% decline from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $191.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.21M 10-Q · filed 2026-08-06 | $18.75M derived: sum of 3 quarters · filed 2026-08-06 | $19.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $17.02M 10-Q · filed 2026-05-07 | $18.56M derived: sum of 2 quarters · filed 2026-05-07 | $19.04M derived: sum of 3 quarters · filed 2026-05-07 | $19.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.02M derived: sum of 2 quarters · filed 2026-03-02 | $2.88M derived: sum of 3 quarters · filed 2026-08-06 | $10.88M 10-K · filed 2026-03-02 |
| 2025-09-30 | $478.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.34M derived: sum of 2 quarters · filed 2026-08-06 | $9.34M 10-Q · filed 2025-11-06 | $9.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $860.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.86M 10-Q · filed 2026-08-06 | $9.02M derived: sum of 3 quarters · filed 2026-08-06 | $9.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-07 | $8.16M derived: sum of 2 quarters · filed 2026-05-07 | $8.25M derived: sum of 3 quarters · filed 2026-05-07 | $8.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $249.00K derived: sum of 2 quarters · filed 2026-03-02 | $300.00K derived: sum of 3 quarters · filed 2026-03-02 | $3.73M 10-K · filed 2026-03-02 |
| 2024-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $134.00K derived: sum of 2 quarters · filed 2025-11-06 | $3.57M 10-Q · filed 2025-11-06 | $3.62M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.48M 10-Q · filed 2025-08-07 | $3.53M derived: sum of 3 quarters · filed 2026-03-02 | $3.61M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $3.43M 10-Q · filed 2025-05-08 | $3.48M derived: sum of 2 quarters · filed 2026-03-02 | $3.56M derived: sum of 3 quarters · filed 2026-03-02 | $3.58M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $121.00K derived: sum of 2 quarters · filed 2026-03-02 | $146.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $97.00K derived: sum of 2 quarters · filed 2024-11-08 | $960.00K 10-Q · filed 2024-11-08 | $981.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $888.00K 10-Q · filed 2024-08-08 | $909.00K derived: sum of 3 quarters · filed 2025-03-06 | $937.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $863.00K 10-Q · filed 2024-05-09 | $884.00K derived: sum of 2 quarters · filed 2025-03-06 | $912.00K derived: sum of 3 quarters · filed 2025-03-06 | $915.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $49.00K derived: sum of 2 quarters · filed 2025-03-06 | $52.00K derived: sum of 3 quarters · filed 2025-03-06 | $468.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $31.00K derived: sum of 2 quarters · filed 2023-11-09 | $447.00K 10-Q · filed 2023-11-09 | $616.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $419.00K 10-Q · filed 2023-08-08 | $588.00K derived: sum of 3 quarters · filed 2024-03-06 | $588.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $416.00K 10-Q · filed 2023-05-09 | $585.00K derived: sum of 2 quarters · filed 2024-03-06 | $585.00K derived: sum of 3 quarters · filed 2024-03-06 | $585.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $169.00K derived: sum of 2 quarters · filed 2024-03-06 | $169.00K derived: sum of 3 quarters · filed 2024-03-06 | $534.00K 10-K · filed 2024-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $365.00K 10-Q · filed 2022-11-09 | $365.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $365.00K 10-Q · filed 2022-08-10 | $365.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $365.00K 10-Q · filed 2022-05-11 | $365.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $63.00K 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $63.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |